George Shapiro
Cardiovascular Disease · White Plains, NYNPI 1205840337
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,704 of the $8,356 with a category attached, or 80.2%. 35 manufacturers reported payments, led by Novartis at 31.3% of the total. Reporting peaked in 2023 at $2,877 and has fallen 90.1% since, to $284 in 2025.
Across 269 payments — averaging $31.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- AbbVie$1K
- Novo Nordisk$666
- Actelion Pharmaceuticals US, Inc.$440
- Johnson & Johnson$375
- AstraZeneca$374
- plus $3K from 29 others
What the payments were for
- Consulting fees$1,50018%
- Food & beverage$6,70480%
- Education$1512%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 40 | $2,619 |
| AbbVie(2 entities) | 47 | $1,223 |
| Novo Nordisk | 28 | $666 |
| Actelion Pharmaceuticals US, Inc. | 18 | $440 |
| Johnson & Johnson | 15 | $375 |
| AstraZeneca | 20 | $374 |
| Amarin Pharma, Inc. | 16 | $279 |
| Boehringer Ingelheim | 13 | $248 |
| Perspectum Diagnostics Ltd | 3 | $222 |
| Boston Scientific | 3 | $168 |
| Cleerly, Inc. | 3 | $165 |
| Lilly USA, LLC | 8 | $157 |
| Celularity Inc. | 1 | $137 |
| Edwards Lifesciences | 6 | $128 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Kowa Pharmaceuticals America, Inc. | 7 | $105 |
| Bardy Diagnostics, Inc. | 7 | $104 |
| Baxter Healthcare | 2 | $104 |
| Merck | 5 | $101 |
| Abbott | 1 | $84 |
| Amgen | 4 | $77 |
| Heartflow, Inc. | 2 | $64 |
| Regeneron Healthcare Solutions, Inc. | 2 | $58 |
| Alnylam Pharmaceuticals Inc. | 2 | $52 |
| G Medical Diagnostic Services, Inc. | 3 | $48 |
| Genentech USA, Inc. | 2 | $42 |
| Hikma Pharmaceuticals USA | 2 | $37 |
| Impulse Dynamics (USA) Inc. | 1 | $22 |
| Galderma Laboratories, L.p. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| AMAG Pharmaceuticals, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Gilead | 1 | $18 |
| United Therapeutics Corporation | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LEQVIO$1,875
- LiverMultiScan$170
- NEXLIZET$125
- NEXLETOL$125
- Cleerly Ischemia$121
- Cleerly Labs$121
- Watchman$121
- XARELTO$105
How this compares
$8,356 in reported general payments places this provider in the 80th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in White Plains
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.